- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03925285
Image Guided Surgery in Sinonasal Inverted Papilloma (SNIPER)
Image Guided Surgery in Sinonasal Inverted Papilloma by Targeting Vascular Endothelial Growth Factor
In sinonasal inverted papilloma (SNIP) it is very challenging to discriminate between tumor and surrounding tissue. Local recurrence is a frequent phenomenon as it occurs in 16.5% of the cases. There is need for an instrument that is able to guide the surgeon in removing all tumor tissue, whereas resection of healthy tissue is minimalized.
Molecular fluorescence guided surgery enables the visualization of targeted tumor-specific biomarkers by using fluorescence, thereby enhancing the contrast between normal mucosa and tumor tissue. The objective of this feasibility study is to determine if the intravenously administered conjugate bevacizumab-IRDye800CW accumulates more in SNIP than in normal sinonasal epithelium.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Rationale: During surgical resection, it is very challenging to discriminate between sinonasal inverted papilloma (SNIP) and surrounding tissue, as SNIP is associated with inducement of granulomatous inflammation of the environment. As a result, the surgeon has to perform a thorough resection in order to remove the complete inverted papilloma, which is associated with substantial morbidity. Clearly, there is need for an instrument that is able to guide the surgeon to discriminate between SNIP and surrounding tissue. Molecular imaging techniques using targeted optical contrast agents is a promising technique to accommodate this need. Vascular Endothelial Growth Factor (VEGF) is overexpressed in SNIP compared to normal epithelium of the sinonasal area and has been used effectively in molecular imaging.
Objectives: The main objective is to study if the conjugate bevacizumab-IRDye800CW accumulates more in sinonasal inverted papilloma than in normal sinonasal mucosa.
Study design: The current study is a non-randomized, non-blinded, prospective, single center, pilot dose-escalation study. A minimum of five and a maximum of eight patients with SNIP will be included. Five patients will be administered with 10 mg bevacizumab-IRDye800CW. An interim analysis is performed after inclusion of the first three patients to determine if a tumor-to-background ratio (TBR) of ≥2 is obtained by either intraoperative fluorescence in vivo measurements or by ex vivo back-table fluorescence imaging. If a TBR of ≥2 is found, inclusion is continued to five patients. If not, the dose is adjusted to 25 mg. Again, a similar interim analysis is performed after inclusion of the first three patients to determine the TBR.
Study population: All included patients will meet the in- and exclusion criteria and have a biopsy confirmed diagnosis of primary or recurrent sinonasal inverted papilloma and are scheduled to undergo surgical resection.
Patient related study procedures: Patients will - after written informed consent - receive an intravenous injection of the fluorescent tracer. The dose will be either 10 mg or 25 mg. Two to four days later, the peroperative fluorescence imaging and multidiameter single fiber reflectance and single fiber fluorescence (MDSFR/SFF) spectroscopy will be performed of the tumor and woundbed.
Main study parameters/endpoints are macroscopic fluorescent signal levels, tumor to background ratio (TBR) and tracer distribution observed by fluorescence imaging and quantification of the fluorescent signal observed by means of MDSFR/SFF spectroscopy. Results of fluorescence imaging and spectroscopy will be correlated with standard histopathological assessment (i.e. hematoxylin and eosin staining) and VEGF immunohistochemistry.
Burden: Time investment: Patients need to visit the UMCG two to four days before their planned surgery which will take approximately two hours. Extra procedures: 1) Intravenous administration of bevacizumab-IRDye800CW. 2)The estimated time for taking fluorescence images and MDSFR/SFF spectroscopy measurements is approximately 15 minutes, which will result in prolongation of general anesthesia with 15 minutes. 3) Prior to surgical resection, the surgeon takes biopsies of fluorescent and non-fluorescent areas, or areas of inverted papilloma and normal mucosal lining of sinonasal cavities involved as identified by the surgeon when intraoperative fluorescent signal is not detected. 4) Immediately after resection of the inverted papilloma, biopsies will be taken from areas in the wound bed showing high fluorescent signal.
Risks: risks to study participants are mainly related to the, already present, risks of the surgical procedure and to the administration of the tracer in increasing dosages. A data safety monitoring board (DSMB) will not be installed as in more than two hundred patients receiving bevacizumab-IRDye800CW, no (serious) adverse events were observed.
Benefit: Patients will have no benefit from this study directly. Surgery will be planned as usual. During surgery, no decisions will be made based on the fluorescence imaging.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Groningen, Netherlands, 9713 GZ
- University Medical Center Groningen
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Biopsy confirmed diagnosis of SNIP and scheduled to undergo surgical resection;
- Age ≥ 18 years;
- Written informed consent;
- Mentally competent person that is able and willing to comply with study procedures.
Exclusion Criteria:
- Medical or psychiatric conditions that compromise the patient's ability to give informed consent;
- Concurrent uncontrolled medical conditions;
- Received an investigational drug within 30 days prior to the dose of bevacizumab-IRDye800CW;
- Tumors at sites of which the surgeon would assess that in vivo imaging would not be feasible;
- History of myocardial infarction, cerebrovascular accident, uncontrolled cardiac heart failure, significant liver disease or unstable angina within 6 months prior to enrollment;
- Inadequately controlled hypertension with or without current antihypertensive medications;
- History of infusion reactions to bevacizumab or other monoclonal antibody therapies;
- Pregnant or lactating women. Documentation of a negative pregnancy test must be available for women of childbearing potential. Woman of childbearing potential are premenopausal women with intact reproductive organs and women less than two years after menopause;
- Lab values that in the opinion of the primary surgeon would prevent surgical resection;
- Life expectancy < 12 weeks;
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: IV fluorescent tracer bevacizumab-800CW
Patients will be administered with 10 or 25 bevacizumab-800CW.
|
Two to four days prior to surgery bevacizumab-800CW will be administered intravenously
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Tumor-to-background ratio of mean fluorescence intensity
Time Frame: Up to day 4
|
Up to day 4
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Histopathologic assessment (H&E staining) of surgical specimen
Time Frame: Approximately two weeks
|
Fluorescence signal will be correlated to histology of tissue (inverted papilloma, inflammation, malignant tumor, healthy tissue).
|
Approximately two weeks
|
VEGF immunohistochemistry of surgical specimen
Time Frame: Approximately two weeks
|
VEGF immunohistochemistry to correlate fluorescence signal with VEGF quantities
|
Approximately two weeks
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms, Glandular and Epithelial
- Neoplasms, Squamous Cell
- Papilloma
- Papilloma, Inverted
- Physiological Effects of Drugs
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Bevacizumab
Other Study ID Numbers
- NL66969.042.18
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Inverted Papilloma
-
Beijing Tongren HospitalRecruitingInverted Papilloma | Draf III Procedure | Naso-septal FlapChina
-
American University of Beirut Medical CenterCompletedBreastfeeding | Inverted NippleLebanon
-
Mayo ClinicWithdrawnInverted Nipple | Retracted NippleUnited States
-
Dana-Farber Cancer InstituteActive, not recruitingFlat Epithelia Atypia | Intraductal Papilloma Without AtypiaUnited States
-
Procare Health Iberia S.L.Adknoma Health ResearchCompletedHuman Papilloma Virus Infection | Human Papilloma Virus | Cervix LesionSpain
-
Emory UniversityNational Institute of Nursing Research (NINR)RecruitingHuman Papilloma Virus | Human Papilloma Virus VaccineUnited States
-
UNC Lineberger Comprehensive Cancer CenterNational Cancer Institute (NCI)Recruiting
-
Groupe Hospitalier Paris Saint JosephRecruitingHuman Papilloma VirusFrance
-
University of VirginiaCompleted
-
Oregon Health and Science UniversityAmerican Cancer Society, Inc.; University of Arkansas; Oregon Health AuthorityActive, not recruitingHuman Papilloma VirusUnited States
Clinical Trials on Bevacizumab-800CW
-
University Medical Center GroningenCompletedVEGF-targeted Fluorescence Near-Infrared (NIR) Endoscopy in (Pre)Malignant Esophageal Lesions (VICE)Esophageal Cancer | DysplasiaNetherlands
-
University Medical Center GroningenCompletedAdenomatous Polyposis ColiNetherlands
-
University Medical Center GroningenUMC UtrechtCompleted
-
University Medical Center GroningenDutch Cancer SocietyCompletedRectal CancerNetherlands
-
University Medical Center GroningenMartini Hospital GroningenCompleted
-
University Medical Center GroningenLeiden University Medical CenterTerminatedPancreatic Cancer | Pancreatic AdenocarcinomaNetherlands
-
University Medical Center GroningenUnknownEndometriosisNetherlands
-
University Medical Center GroningenNot yet recruitingBarrett Esophagus | Colon Carcinoma | Gastrointestinal Dysplasia
-
Meander Medical CenterCompletedColorectal Neoplasms | Sentinel Lymph Node | Colon Neoplasm | FluorescenceNetherlands
-
University Medical Center GroningenCompletedCrohn Disease | Colitis, UlcerativeNetherlands